MX2023013886A - Pemafibrato y/o tofogliflozin para uso en el tratamiento de enfermedad del higado. - Google Patents

Pemafibrato y/o tofogliflozin para uso en el tratamiento de enfermedad del higado.

Info

Publication number
MX2023013886A
MX2023013886A MX2023013886A MX2023013886A MX2023013886A MX 2023013886 A MX2023013886 A MX 2023013886A MX 2023013886 A MX2023013886 A MX 2023013886A MX 2023013886 A MX2023013886 A MX 2023013886A MX 2023013886 A MX2023013886 A MX 2023013886A
Authority
MX
Mexico
Prior art keywords
pemafibrate
tofogliflozin
treatment
liver disease
nash patients
Prior art date
Application number
MX2023013886A
Other languages
English (en)
Spanish (es)
Inventor
Noboru KANETA
Ryu Oshima
Shona Sanchita Pendse
Ryohei TANIGAWA
Original Assignee
Kowa Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co filed Critical Kowa Co
Publication of MX2023013886A publication Critical patent/MX2023013886A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2023013886A 2021-05-27 2022-05-25 Pemafibrato y/o tofogliflozin para uso en el tratamiento de enfermedad del higado. MX2023013886A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163194088P 2021-05-27 2021-05-27
PCT/IB2022/054867 WO2022249071A1 (en) 2021-05-27 2022-05-25 Pemafibrate and/or tofogliflozin for use in treating liver disease

Publications (1)

Publication Number Publication Date
MX2023013886A true MX2023013886A (es) 2024-04-19

Family

ID=82020168

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013886A MX2023013886A (es) 2021-05-27 2022-05-25 Pemafibrato y/o tofogliflozin para uso en el tratamiento de enfermedad del higado.

Country Status (10)

Country Link
US (1) US20240277745A1 (cg-RX-API-DMAC10.html)
EP (1) EP4346809B1 (cg-RX-API-DMAC10.html)
JP (1) JP2024520020A (cg-RX-API-DMAC10.html)
KR (1) KR20240013203A (cg-RX-API-DMAC10.html)
CN (1) CN117677385A (cg-RX-API-DMAC10.html)
AU (1) AU2022282651A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023024701A2 (cg-RX-API-DMAC10.html)
CA (1) CA3221073A1 (cg-RX-API-DMAC10.html)
MX (1) MX2023013886A (cg-RX-API-DMAC10.html)
WO (1) WO2022249071A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2024014524A1 (cg-RX-API-DMAC10.html) * 2022-07-15 2024-01-18
CN115991682A (zh) * 2023-03-21 2023-04-21 广州佳途科技股份有限公司 一种培马贝特-d4的制备方法及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI696462B (zh) * 2013-07-10 2020-06-21 日商興和股份有限公司 非酒精性脂肪性肝疾病治療劑
EP3569250B1 (en) * 2017-01-11 2025-04-30 Kowa Company, Ltd. Pemafibrate in combination with a sglt2 inhibitor for the prophylactic or therapeutic treatment of liver diseases nonalcoholic fatty liver disease

Also Published As

Publication number Publication date
CN117677385A (zh) 2024-03-08
BR112023024701A2 (pt) 2024-02-15
AU2022282651A1 (en) 2023-12-07
KR20240013203A (ko) 2024-01-30
EP4346809A1 (en) 2024-04-10
CA3221073A1 (en) 2022-12-01
JP2024520020A (ja) 2024-05-21
WO2022249071A1 (en) 2022-12-01
EP4346809B1 (en) 2026-07-15
US20240277745A1 (en) 2024-08-22

Similar Documents

Publication Publication Date Title
MX2023003677A (es) Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos.
WO2006127007A3 (en) Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
BRPI0409919A (pt) combinações para o tratamento de doenças envolvendo proliferação, migração ou apoptose celular de células de células de mieloma, ou angiogênese
WO2008133928A3 (en) Mucin glycoproteins and their use for treatment of epithelial lesions and mucin dependent disorders
WO2012071526A3 (en) Irreversible electroporation using tissue vasculature to treat aberrant cell masses or create tissue scaffolds
MX2009012197A (es) Metodos para tratamiento de ulceras en la piel.
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
MX2021000955A (es) Terapia de incremento mitocondrial para enfermedades mitocondriales primarias.
MX2025003477A (es) Uso de reboxetina para el tratamiento de narcolepsia
MX391565B (es) Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
WO2006014159A3 (en) Methods of using regenerative cells in the treatment of musculoskeletal disorders
IL308152A (en) 2-fluoroalkyl-4,3,1-oxadiazol-5-yl-thiazole, HDAC6 inhibitors for use in the treatment of metabolic disease and HFPEF
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2021002349A (es) Inhibidores de calicreína en plasmá y usos de los mismos para tratar ataque de angioedema hereditario.
JO3709B1 (ar) تركيبة صيدلانية أو مجموعة طبية للاستخدام في علاج سرطان لدى كائن ثديي تتضمن إنزيم الأسباراجيناز وإنزيم الميثيونيناز
MY203136A (en) Plasminogen treatment of conditions associated with pai-1 overexpression
MX2023003675A (es) Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos.
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
BR112023024701A2 (pt) Métodos de tratamento de doenças do fígado
MX2023006906A (es) Lubricante a base de microparticulas de hidrogel.
MA27607A1 (fr) Peptides cyto-modulateurs pour traiter la cystite interstitielle
WO2021044405A3 (en) Therapeutic apoptotic cells for treatment of osteoarthritis
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
EP4321220A3 (en) A1at for reducing risk of onset of acute graft versus host disease after hematopoeitic cell transplantation
WO2021034996A3 (en) Treatment of cardiovascular diseases